- Home
- TASK vs NRIX Comparison
TASK vs NRIX Comparison
Compare TASK & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TASK
- NRIX
- Stock Information
- Founded
- TASK 2008
- NRIX 2009
- Country
- TASK United States
- NRIX United States
- Employees
- TASK N/A
- NRIX N/A
- Industry
- TASK Retail: Computer Software & Peripheral Equipment
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- TASK Technology
- NRIX Health Care
- Exchange
- TASK Nasdaq
- NRIX Nasdaq
- Market Cap
- TASK 1.5B
- NRIX 1.4B
- IPO Year
- TASK 2021
- NRIX 2020
- Fundamental
- Price
- TASK $16.77
- NRIX $19.14
- Analyst Decision
- TASK Buy
- NRIX Strong Buy
- Analyst Count
- TASK 8
- NRIX 17
- Target Price
- TASK $17.25
- NRIX $30.29
- AVG Volume (30 Days)
- TASK 285.8K
- NRIX 832.5K
- Earning Date
- TASK 02-26-2025
- NRIX 02-13-2025
- Dividend Yield
- TASK N/A
- NRIX N/A
- EPS Growth
- TASK 29.08
- NRIX N/A
- EPS
- TASK 0.58
- NRIX N/A
- Revenue
- TASK $955,007,000.00
- NRIX $56,424,000.00
- Revenue This Year
- TASK $9.16
- NRIX N/A
- Revenue Next Year
- TASK $9.71
- NRIX $3.79
- P/E Ratio
- TASK $28.72
- NRIX N/A
- Revenue Growth
- TASK 2.43
- NRIX N/A
- 52 Week Low
- TASK $10.56
- NRIX $7.65
- 52 Week High
- TASK $19.60
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- TASK 55.41
- NRIX 45.09
- Support Level
- TASK $14.31
- NRIX $17.50
- Resistance Level
- TASK $17.09
- NRIX $20.50
- Average True Range (ATR)
- TASK 0.88
- NRIX 1.12
- MACD
- TASK -0.04
- NRIX 0.16
- Stochastic Oscillator
- TASK 76.26
- NRIX 54.67
About TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to inventive and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.